Top 10 Urology Times men’s health articles of 2025

Urology Times’ top men’s health articles of 2025 reflect the growing recognition of current gaps in care and the promising developments on the horizon. Key stories included the FDA’s label change for testosterone products and the emergence artificial intelligence (AI) in the field. Other advances include the development of a novel injectable male birth control and the expansion of GLP-1 receptor agonists (RA) into the men’s health space.

ADAM, a long-term, injectable male birth control, shows promise at AUA 2025

Data presented at the American Urological Association (AUA) 2025 Annual Meeting showed that ADAM, a reversible, non-hormonal hydrogel male contraceptive injected into the vas deferens, demonstrated a favorable 90-day safety profile in a first-in-human trial of 25 men, with no procedural adverse events reported. Additional company-reported data suggest sustained contraceptive efficacy up to 24 months, including 2 cases of azoospermia, supporting ADAM’s potential as a long-acting, reversible male contraception option.

FDA issues labeling changes for testosterone products following TRAVERSE, postmarket studies

On March 3, 2025, the FDA issued class-wide labeling changes for testosterone products, adding warnings about increased blood pressure based on postmarket ABPM studies and removing boxed warning language on cardiovascular risk following results from the TRAVERSE trial. TRAVERSE showed no clinically meaningful difference in the incidence of major adverse cardiovascular events between high-risk patients receiving testosterone placement therapy vs placebo. The label update retained the 'limitation of use' language for age-related hypogonadism.

AUA 2025: GLP-1 RAs could improve sperm count in overweight men

A retrospective analysis presented at AUA 2025 found that GLP-1 receptor agonist use among overweight or obese men was associated with statistically significant improvements in sperm count compared with matched nonusers. However, GLP-1 RA exposure was not linked to improvements in sperm motility and was associated with fewer improvements in semen volume, suggesting mixed effects on male fertility parameters.

Study links poor semen quality with shorter life span

A large cohort study published in Human Reproduction found that higher semen quality in nearly 80,000 men was associated with longer life expectancy, with men in the highest total motile sperm count category living an average of 2.7 years longer than those with the poorest sperm quality. The findings suggest semen quality may serve as an early biomarker of overall health and future disease risk, although the biological mechanisms underlying this association remain unclear.

Sildenafil/Clomipramine Combo Boosts Outcomes in Premature Ejaculation

A phase 3 trial presented at AUA 2025 showed that combination therapy with sildenafil 50 mg plus clomipramine 15 mg significantly improved intravaginal ejaculatory latency time and patient-reported outcomes compared with either agent alone in men with premature ejaculation without erectile dysfunction. The combination demonstrated greater efficacy with a safety profile comparable to monotherapy, supporting its potential as a new treatment option for premature ejaculation.

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

In this episode of Pearls & Perspectives, host Amy Pearlman, MD, interviews John P. Mulhall, MD, who provides an evidence-based discussion on testosterone evaluation, treatment decision-making, and evolving views on prostate cancer risk. The conversation addresses measurement and symptom pitfalls, functional hypogonadism, rational testosterone and clomiphene prescribing, and emerging strategies for managing men before and after prostate cancer treatment.

FDA market clearance sought for Separo sealing system for vasectomy

Signati Medical filed a de novo application with the FDA seeking market clearance for its Separo vessel sealing system for vasectomy. The application is supported by favorable Good Laboratory Practice data and an investigational device exemption study in which all 8 patients achieved acceptable post-vasectomy azoospermia outcomes with no device-related adverse events. In an interview with Urology Times, principal investigator Matthew J. Mutter, MD, highlighted the system’s potential to modernize vasectomy by enabling a fast, assistant-free procedure with an excellent safety and pain profile.

FDA clears chemiluminescence-based immunoassay for free testosterone

On January 10, 2025, the FDA granted 510(k) clearance to EUROIMMUN’s automated chemiluminescence-based immunoassay for the quantitative measurement of free testosterone, making it the first FDA-cleared test of its kind. The assay delivers results in 48 minutes, supports diagnosis of conditions such as hypogonadism and polycystic ovarian syndrome, and complements EUROIMMUN’s existing automated total testosterone testing platform.

AI and wearables: The new age of smart sex

In an editorial for Urology Times, Dayna R. Smerina and Amy Pearlman, MD, highlighted the growing role of AI and wearable devices in sexual medicine, including AI tools for STI screening and wearable technologies for assessing and improving male sexual function. They also note promising applications such as AI-driven lesion assessment, erection-tracking rings, and devices for managing premature ejaculation, while emphasizing ethical considerations, privacy, and equitable access as key factors for the responsible integration of these technologies.

Label change for testosterone: Implications for urologists, prescribers, and patients

Experts offer their thoughts on the FDA’s February 2025 decision to update testosterone labeling to reflect that the therapy does not increase the risk of major adverse cardiovascular events. According to the experts, the label changes have important implications for patient counseling and access to appropriate care.